Is There a Role for Complement in Systemic Hypertension?
In general, there are hints that complement may be involved in the vascular remodeling of hypertension (1) , but the evidence is quite limited. Over the past two decades, attention has been focused on the roles of C5a and its receptors (C5aR1 and C5aR2) in inflammatory responses developing after infectious conditions, ischemia-reperfusion, acute lung injury, and sepsis (3) , to cite just a few examples. It has been known for several decades that C5a binds with high affinity to polymorphonuclear neutrophils via cell surface C5aRs, triggering a series of signal transduction pathways that activate the NF-B system with resultant production of proinflammatory mediators. It has become evident that, in addition to phagocytes, other cell types also have binding sites for C5a (fibroblasts, endothelial cells, cardiomyocytes, etc.). C5a-binding sites may be transcriptionally upregulated on different cell surfaces in a variety of circumstances, such as sepsis. In most cases, upregulation of C5aR1 has been associated with enhanced proinflammatory outcomes. Inflammatory damage in the lung, kidneys, and liver may be irreversible with resultant fibrosis or the outcomes may be reversible with conversion of damaged tissues to their preinjury state.
Strategies for Blockade of Complement Activation or Its Activation Products
The most striking translational application of complement research has been seen with a C5-blocking monoclonal antibody (eculizumab), used in patients with paroxysmal nocturnal hemoglobinuria (9) . Clinical exacerbations of paroxysmal nocturnal hemoglobinuria are due to defective anchoring proteins for CD55 and CD59, which regulate complement activation on cell surfaces (erythrocytes, in this case). The same monoclonal antibody to C5 has been approved for use in pediatric cases of atypical hemolytic uremic syndrome, a complement-related microthrombotic disorder after a flu-like syndrome and often leading to suppressed renal glomerular function (5). In addition, there are currently phase II clinical trials in Germany involving patients with sepsis. This intervention features the use of a "humanized" neutralizing monoclonal antibody to human C5a (2). To date, the antibody appears safe for use in humans, although it is too early to know if the antibody intervention will be clinically effective in humans with sepsis.
There has been interest in strategies that block convertases for C3 and C5. These convertases cleave either C3 into C3a and C3b or C5 into C5a and C5b. C3a and C5a are powerful proinflammatory anaphylatoxins, whereas C3b is an important opsonic-promoting factor. C5b is interactive with C6 -C9 to produce the membrane attack complex, which can cause lysis of cells and infectious agents such as bacteria, viruses, and protozoa. The group at the University of Pennsylvania over several years has developed a cyclic peptide (compstatin) that blocks C3 convertase and may be useful in humans with complement-mediated disorders (8) . A concern about this approach is that the amount of blockade of complement will have to be carefully calibrated to avoid excessive reduction in C3b generation, which could significantly interfere with the opsonic innate immune pathways. One strategy would be to use the drug in a manner that does not result in the dissemination of the drug throughout the body. Accordingly, the drug might find application in age-associated macular degeneration in the eye, in which it could be slowly released near the retina. Currently, the only Federal Drug Administration-approved drug for macular degeneration involves monthly injections of antibody to VEGF into the vitreous (1a) . This intervention appears to be effective in reducing the progression of macular degeneration.
Possible Role of C5aR2 in Events of Ischemia-Reperfusion or Hypertension
In the report by Weiss et al. (10) , the focus was exclusively on the role of C5aR1, which is the more common C5aR reacting with C5a. C5aR2 (originally designated as C5L2) was described as a "C5a default receptor" and was thought to be more reactive with C5a des arg. C5a des arg is the product of C5a reacting with carboxy peptidase N, resulting in the loss of most of the chemotactic activity. Early on, it was thought that C5aR2 regulated the amount of C5a so as to prevent excessive buildup of C5a. Accordingly, C5aR2 reacting with C5a would attenuate inflammatory damage in tissues (6) . Another vexing issue is the finding that C5aR1 is chiefly on the surface of cells (especially phagocytes). A recent study (6) of C5aR2 has suggested it is chiefly located in the cytosol, raising the question of how C5a could gain access to cytosolic C5aR2. Disputes continue as to whether, on balance, C5aR2 is proinflammatory or antiinflammatory. For these reasons, designing therapies that would target either C5aR1 or C5aR2 for block-ade or both have been complicated because of the conflicting data related to the biological activities of the two receptors.
Complement Activation Inside the Cell
Complement has been defined as a series of many proteins, which, when sequentially activated, result in protein/peptide products in the extracellular compartment. These products have biological activities resulting in proinflammatory responses, cell lysis, and activation of the innate immune system. We are now challenged by a recent report (7) describing intracellular activation of C3 in CD4 ϩ T cells, due to activation of the protease cathepsin L, which generates intracellular C3a and C3b from C3. It has been suggested that C3a is necessary for T cell survival and autocrine production of proinflammatory cytokines by T cells. Accordingly, the theory would suggest that intracellular activation (cleavage) of C3 in T cells promotes important T cell responses, but, in certain situations, this may lead to harmful proinflammatory outcomes. It will be important to define further the details of biological pathways and outcomes of intracellular activation of complement, including if there is a parallel pathway for the intracellular activation of C5, as well as determining what other types of cells possess similar intracellular pathways of complement activation.
Concluding Remarks
The Weiss et al. report (10) underscores the potential dichotomy in the roles of C5aR1 ϩ cells in hypertension-induced changes in the kidney and the heart. This would suggest the likelihood of different pathophysiological pathways related to C5aR1, depending on the organ under study. If such conclusions are to be extended, this represents an important problem in therapeutic interventions aimed at blockade of C5a or its receptors. Without additional data, it is impossible to predict if blockade of C5a or its receptors would be therapeutically advantageous or possibly harmful.
The other important message is that the report by Liszewski et al. (7) suggests that a new direction for complement research is emerging, namely, intracellular complement activation, which has not been previously described. This could have enormous implications related to our understanding about the roles of extracellular and intracellular activation of complement.
To an extent, over 50 yr, biochemical details have emerged for complement proteins, complement activation pathways, complement regulatory proteins, and molecular structural details of complement activation products and receptors. Many scientists felt after so much progress that there was little more to be learned about complement. How wrong they were!
